Saturday 17 October 2026
Export VECT’s income statement to Excel — free account
VectivBio Holding AG
VECT Healthcare Biotechnology
VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
Follow VECT
| Older periods | Jun '21 | Dec '21 | Jun '22 | Dec '22 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | 0.00% | 0.00% | (147.18%) | |
| — | 0.00% | 0.00% | (111.86%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (157.55%) | (133.16%) | (89.51%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | — | — | (176.61) | |
Capital Expenditures |
— | — | — | (0.24) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (39.68%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | — | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.98 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 2.05 | |
Capex/Depreciation |
— | — | — | (0.26) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates